Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
- Conditions
- Interventions
- Drug: FludarabineRadiation: Total-Body IrradiationProcedure: Donor Lymphocyte InfusionDrug: CyclophosphamideDrug: TacrolimusDrug: Mycophenolate MofetilProcedure: Hematopoietic Cell TransplantationProcedure: Bone Marrow Aspiration and BiopsyDrug: MelphalanProcedure: Diagnostic ImagingProcedure: Biospecimen Collection
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 63
- Registration Number
- NCT05031897
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Koen van Besien
- Registration Number
- NCT05013437
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 6
- Registration Number
- NCT04994977
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Guenther Koehne
- Target Recruit Count
- 20
- Registration Number
- NCT04982354
- Locations
- 🇺🇸
Miami Cancer Institute at Baptist Health of South Florida, Miami, Florida, United States
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04937634
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
- Conditions
- Interventions
- Drug: BusulfanRadiation: Total-body irradiationDrug: MelphalanDrug: CyclophosphamideDrug: FludarabineProcedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)Procedure: Bone Marrow Hematopoietic Stem Cell TransplantationDrug: Post-transplant CyclophosphamideDrug: MesnaDrug: TacrolimusDrug: Mycophenolate MofetilOther: Patient-Reported Outcomes
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-05-23
- Target Recruit Count
- 300
- Registration Number
- NCT04904588
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Ohio State Medical Center, James Cancer Center, Columbus, Ohio, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Eye & ENT Hospital of Fudan University
- Target Recruit Count
- 18
- Registration Number
- NCT04903678
- Locations
- 🇨🇳
Fudan Eye & ENT Hospital, Shanghai, China
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
- Conditions
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT04872595
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 6
- Registration Number
- NCT04812470
- Locations
- 🇸🇪
Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
Topotecan and Melphalan for Retinoblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT04799002
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.